CHF Solutions

CHF Solutions (NSDQ:CHFS) today released results from a study of its ultrafiltration, such as with its Aquadex Flex Flow system, as compared to diuretic therapy for treating heart failure patients, touting a reduction in hospital duration and readmissions.

The Eden Prairie, Minn.-based company said that results from the study were published in the Journal of Medical Economics.

In the study, investigators examined clinical data from literature and hospital data from the Healthcare Cost and Utilization Project to follow decision analytic framework and explored treatment decisions, costs and outcomes for treating heart failure patients with fluid overload with either ultrafiltration or diuretic therapy.

Results from the trial indicated that while the costs of ultrafiltration therapy were higher, fluid removal with ultrafiltration resulted in reduced hospital readmissions and cost savings of approximately $3,975, or 15%, when compared to diuretic therapy.

“We have for some time highlighted that one of the key advantages to ultrafiltration therapy with the Aquadex system was the cost savings to the hospital and the healthcare system in general. It is gratifying to have this claim validated in a peer-reviewed academic journal that covers economic assessments of therapeutics and medical device interventions.  We continue to believe that ultrafiltration therapy provides a much needed clinical alternative to diuretic therapy that also provides important economic benefits,” chair & CEO John Erb said in a press release.

Earlier this month, CHF Solutions said that a stock-and-warrants offering brought in more than $12 million.

The post CHF Solutions touts reduced cost, hospital stays in Aquadex Flex Flow ultrafiltation study appeared first on MassDevice.

Source link